Cytokinetics INC 10-Q quarterly reports

Cytokinetics, Inc. filed its Q1 2026 10-Q report, detailing financial performance, progress on MYQORZO commercialization, and ongoing clinical development programs.

Cytokinetics reports increased net loss and R&D expenses in Q3 2025, with aficamten's FDA PDUFA date extended to December 26, 2025, due to REMS submission.

Cytokinetics reports significant revenue growth from new collaborations and positive clinical trial results for Aficamten, despite increased operating losses and a PDUFA date extension.

Cytokinetics reports a net loss of $161.4 million for Q1 2025, with key updates on aficamten's regulatory pathway and ongoing clinical trials.

Cytokinetics' third quarter 2024 report details financial results and provides updates on key clinical programs, including aficamten and omecamtiv mecarbil.

Cytokinetics' second quarter 2024 filing details financial results, ongoing research and development activities, and recent financing transactions.

Cytokinetics' first quarter 2024 results show a net loss of $135.6 million, with ongoing investment in research and development, particularly in cardiac muscle contractility programs.